Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.Antimicrobial agents and chemotherapy · 2011
   Trial
2. Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.African journal of laboratory medicine · 2018
   Article
3. Lower genetic variability of HIV-1 and antiretroviral drug resistance in pregnant women from the state of Pará, Brazil.BMC infectious diseases · 2017
   Article
4. Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System.PloS one · 2016
   Article
5. Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China.PloS one · 2014
   Article
6. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.Journal of clinical microbiology · 2013
   Article
7. Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.BMC infectious diseases · 2013
   Article
8. Base-calling algorithm with vocabulary (BCV) method for analyzing population sequencing chromatograms.PloS one · 2013
   Article
9. Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.AIDS research and treatment · 2012
   Article
10. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.PloS one · 2012
    Article
11. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.PloS one · 2012
    Article
12. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
13. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.Journal of virology · 2011
    Article
14. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.PloS one · 2010
    Article

Corrections and comments

• Comment on
  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as